Emmanouil Saloustros

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2626640/publications.pdf

Version: 2024-02-01

97 papers	6,395 citations	126907 33 h-index	79698 73 g-index
106 all docs	106 docs citations	106 times ranked	10297 citing authors

#	Article	IF	Citations
1	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6
2	Physiciansâ€™ experience, practice and education, on genetic testing and genetic counseling: a nationwide survey study in Greece. Familial Cancer, 2022, 21, 479-487.	1.9	1
3	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
4	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA Oncology, 2022, 8, e216744.	7.1	51
5	Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group. Current Oncology, 2022, 29, 1237-1251.	2.2	1
6	Common Susceptibility Loci for Male Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 453-461.	6.3	12
7	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. British Journal of Cancer, 2021, 124, 842-854.	6.4	5
8	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
9	Breast Cancer Risk Genes â€" Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	27.0	532
10	Adolescents and young adults (AYA) with cancer: a position paper from the AYA Working Group of the European Society for Medical Oncology (ESMO) and the European Society for Paediatric Oncology (SIOPE). ESMO Open, 2021, 6, 100096.	4.5	104
11	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. Human Genetics and Genomics Advances, 2021, 2, 100042.	1.7	6
12	Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. Cancer Immunology, Immunotherapy, 2021, , 1.	4.2	16
13	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6
14	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7
15	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	6.4	9
16	Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 2021, 596, 393-397.	27.8	183
17	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	2.5	19
18	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	3.3	2

#	Article	IF	Citations
19	Vaccine third dose and cancer patients: necessity or luxury?. ESMO Open, 2021, 6, 100306.	4.5	9
20	Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk. International Journal of Cancer, 2020, 146, 2130-2138.	5.1	13
21	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
22	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	6.2	39
23	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
24	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
25	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. Cancer Genomics and Proteomics, 2020, 17, 181-193.	2.0	2
26	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
27	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
28	BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. International Journal of Cancer, 2020, 147, 1334-1342.	5.1	7
29	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
30	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
31	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
32	Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey. ESMO Open, 2019, 4, e000467.	4.5	14
33	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
34	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
35	Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: Updated results of an observational study. Annals of Oncology, 2019, 30, vii13.	1.2	0
36	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711

#	Article	IF	Citations
37	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	1.9	81
38	Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology. Oncotarget, 2019, 10, 1209-1216.	1.8	9
39	Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open, 2018, 3, e000285.	4.5	169
40	Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer. Breast Cancer Research and Treatment, 2018, 169, 105-113.	2.5	37
41	Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. AÂMulticenter Phase II Trial by the Hellenic Oncology Research Group. Clinical Breast Cancer, 2018, 18, 88-94.	2.4	17
42	Extending the clinical phenotype associated with biallelic NTHL1 germline mutations. Clinical Genetics, 2018, 94, 588-589.	2.0	23
43	Lymph Node Cellular Dynamics in Cancer and HIV: What Can We Learn for the Follicular CD4 (Tfh) Cells?. Frontiers in Immunology, 2018, 9, 2233.	4.8	10
44	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
45	Genetic Evidence for the Association between Schizophrenia and Breast Cancer. Journal of Psychiatry and Brain Science, 2018, 3, .	0.5	10
46	The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey. ESMO Open, 2017, 2, e000252.	4.5	48
47	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
48	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
49	Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group. British Journal of Cancer, 2017, 117, 164-170.	6.4	9
50	Prkar1a gene knockout in the pancreas leads to neuroendocrine tumorigenesis. Endocrine-Related Cancer, 2017, 24, 31-40.	3.1	26
51	Celecoxib treatment of fibrous dysplasia (FD) in a human FD cell line and FD-like lesions in mice with protein kinase A (PKA) defects. Molecular and Cellular Endocrinology, 2017, 439, 165-174.	3.2	5
52	Abstract 3740: The pursue of genetic mechanisms underlying supreme response to pazopanib treatment. , 2017, , .		0
53	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecologic Oncology, 2016, 141, 454-460.	1.4	85
54	Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Annals of Oncology, 2016, 27, 1873-1878.	1.2	21

#	Article	IF	Citations
55	Bone Abnormalities in Mice with Protein Kinase A (PKA) Defects Reveal a Role of Cyclic AMP Signaling in Bone Stromal Cell-Dependent Tumor Development. Hormone and Metabolic Research, 2016, 48, 714-725.	1.5	6
56	Bevacizumab plus dose-dense neoadjuvant FEC followed by docetaxel chemotherapy in patients with HER2-negative breast cancer: a multicentre, phase 2 study by the Hellenic Oncology Research Group. Annals of Oncology, 2016, 27, vi62.	1.2	0
57	Celecoxib reduces glucocorticoids in vitro and in a mouse model with adrenocortical hyperplasia. Endocrine-Related Cancer, 2016, 23, 15-25.	3.1	11
58	Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review). International Journal of Oncology, 2016, 48, 869-885.	3.3	302
59	Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. Cancer Letters, 2016, 370, 302-312.	7.2	47
60	Abstract 3422: The influence of genetic and clinical factors on the outcome following a diagnosis of small cell carcinoma of the ovary, hypercalcemic type. , 2016, , .		0
61	Hematopoietic neoplasms in Prkar2a-deficient mice. Journal of Experimental and Clinical Cancer Research, 2015, 34, 143.	8.6	8
62	Is IGSF1 involved in human pituitary tumor formation?. Endocrine-Related Cancer, 2015, 22, 47-54.	3.1	16
63	Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?. Breast, 2015, 24, 201-207.	2.2	97
64	Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Annals of Oncology, 2015, 26, 1333-1340.	1.2	153
65	Palliative chemotherapy for patients with breast cancer. Lancet Oncology, The, 2015, 16, 1453-1454.	10.7	0
66	Haploinsufficiency for either one of the type-II regulatory subunits of protein kinase A improves the bone phenotype ofPrkar1a+/â^'mice. Human Molecular Genetics, 2015, 24, 6080-6092.	2.9	9
67	Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment, 2014, 148, 591-597.	2.5	10
68	Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nature Genetics, 2014, 46, 438-443.	21.4	383
69	Lung cancer in the era of Greek economic crisis. Lung Cancer, 2014, 86, 112-113.	2.0	7
70	Abstract LB-89: Germ-line and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. , 2014, , .		0
71	Abstract 3854: Novel hematopoietic neoplasms in prkar2a- deficient mice.. , 2013, , .		0
72	Potential Late Effect of Gonadotropin-Releasing Hormone Agonists in Combination With Chemotherapy for Early Breast Cancer. Journal of Clinical Oncology, 2012, 30, 3311-3312.	1.6	3

#	Article	IF	Citations
73	KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome. Endocrine-Related Cancer, 2012, 19, 255-260.	3.1	38
74	Coffee Drinking and Mortality. New England Journal of Medicine, 2012, 367, 575-577.	27.0	4
75	Large-cell calcifying Sertoli cell tumors of the testes in pediatrics. Current Opinion in Pediatrics, 2012, 24, 518-522.	2.0	71
76	Docetaxel (D), Gemcitabine (G) and Bevacizumab (BEV) as Salvage Chemotherapy (CT) for HER-2 Negative Metastatic Breast Cancer (MBC). Annals of Oncology, 2012, 23, ix139.	1.2	0
77	The cAMP pathway and the control of adrenocortical development and growth. Molecular and Cellular Endocrinology, 2012, 351, 28-36.	3.2	48
78	Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer, 2012, 118, 493-499.	4.1	83
79	Abstract 1360: A mouse model of double heterozygosity for protein kinase A regulatory subunits promotes osteoblastic differentiation of cAMP-induced bone tumors. , 2012, , .		0
80	Abstract 954: COX-2 inhibition reduces bone tumor growth in animal models:A role for celecoxib treatment in cAMP/protein kinase A-induced tumors. , 2012, , .		0
81	Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Research, 2011, 13, R60.	5.0	74
82	Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. Expert Opinion on Pharmacotherapy, 2011, 12, 851-863.	1.8	21
83	Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab. Cancer Chemotherapy and Pharmacology, 2011, 68, 217-223.	2.3	6
84	Pancreatic Ductal and Acinar Cell Neoplasms in Carney Complex: A Possible New Association. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1888-E1895.	3.6	38
85	Case 17-2011: A Woman with a Mass in the Breast and Overlying Skin Changes. New England Journal of Medicine, 2011, 365, 1259-1260.	27.0	0
86	Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. Breast Cancer Research and Treatment, 2010, 123, 581-585.	2.5	15
87	Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma. Journal of Neuro-Oncology, 2010, 97, 291-294.	2.9	10
88	Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer. Annals of Oncology, 2010, 21, 1729-1730.	1.2	6
89	Screening and Detection of Breast Cancer and Prostate Cancer. JAMA - Journal of the American Medical Association, 2010, 303, 1032.	7.4	0
90	Favorable Clinical Course of Patients Experiencing Bevacizumab-Induced Proteinuria. Case Reports in Oncology, 2010, 3, 368-371.	0.7	5

#	Article	IF	Citations
91	Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis. Future Oncology, 2010, 6, 209-219.	2.4	14
92	Advanced Nonâ€“Small-Cell Lung Cancer in the Elderly. Clinical Lung Cancer, 2009, 10, 158-167.	2.6	10
93	Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: An analysis of microbiological data. Scandinavian Journal of Infectious Diseases, 2008, 40, 414-419.	1.5	25
94	Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2008, 8, 1207-1222.	2.4	47
95	Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opinion on Pharmacotherapy, 2008, 9, 2603-2616.	1.8	105
96	A nosocomial, foodborne outbreak of Salmonella Enterica serovar Enteritidis in a University hospital in Greece: the importance of establishing HACCP systems in hospital catering. Journal of Hospital Infection, 2007, 66, 194-196.	2.9	16
97	Morganella morganii Infections in a General Tertiary Hospital. Infection, 2006, 34, 315-321.	4.7	65